[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201507595XA - Processes and intermediates for preparing a medicament - Google Patents

Processes and intermediates for preparing a medicament

Info

Publication number
SG11201507595XA
SG11201507595XA SG11201507595XA SG11201507595XA SG11201507595XA SG 11201507595X A SG11201507595X A SG 11201507595XA SG 11201507595X A SG11201507595X A SG 11201507595XA SG 11201507595X A SG11201507595X A SG 11201507595XA SG 11201507595X A SG11201507595X A SG 11201507595XA
Authority
SG
Singapore
Prior art keywords
intermediates
medicament
preparing
processes
Prior art date
Application number
SG11201507595XA
Inventor
Philip Pye
Haim Cyril Ben
Matteo Conza
Ioannis Nicolaos Houpis
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SG11201507595XA publication Critical patent/SG11201507595XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11201507595XA 2013-03-15 2014-03-11 Processes and intermediates for preparing a medicament SG11201507595XA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361786842P 2013-03-15 2013-03-15
EP13159470 2013-03-15
EP13197813 2013-12-17
PCT/EP2014/054621 WO2014139970A1 (en) 2013-03-15 2014-03-11 Processes and intermediates for preparing a medicament

Publications (1)

Publication Number Publication Date
SG11201507595XA true SG11201507595XA (en) 2015-10-29

Family

ID=51535892

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201809696UA SG10201809696UA (en) 2013-03-15 2014-03-11 Processes and intermediates for preparing a medicament
SG11201507595XA SG11201507595XA (en) 2013-03-15 2014-03-11 Processes and intermediates for preparing a medicament

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201809696UA SG10201809696UA (en) 2013-03-15 2014-03-11 Processes and intermediates for preparing a medicament

Country Status (19)

Country Link
EP (1) EP2970291B1 (en)
JP (1) JP6777398B2 (en)
KR (2) KR102377688B1 (en)
CN (2) CN112608298A (en)
AU (2) AU2014230935A1 (en)
BR (1) BR112015021856A2 (en)
CA (1) CA2901510C (en)
DK (1) DK2970291T3 (en)
EA (1) EA201591685A1 (en)
ES (1) ES2924193T3 (en)
HR (1) HRP20220628T1 (en)
HU (1) HUE058914T2 (en)
LT (1) LT2970291T (en)
MX (2) MX2015012731A (en)
MY (1) MY194905A (en)
PE (1) PE20151652A1 (en)
SG (2) SG10201809696UA (en)
SI (1) SI2970291T1 (en)
WO (1) WO2014139970A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2722524T3 (en) 2011-09-02 2019-08-13 Incyte Holdings Corp Heterocyclamines as pi3k inhibitors
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
CN105884747B (en) * 2014-08-28 2021-01-05 首药控股(北京)有限公司 Preparation method for preparing Bruton's Tyrosine Kinase (BTK) kinase inhibitor
CN104447761A (en) * 2014-11-27 2015-03-25 广东东阳光药业有限公司 Method for preparing pyrazole derivative
US10266535B2 (en) 2015-01-21 2019-04-23 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Inhibitor of FLT3 kinase and use thereof
CN105481862B (en) * 2015-01-21 2018-08-21 中国科学院合肥物质科学研究院 The new inhibitor and application thereof of FLT3 kinases
SG11201706917WA (en) * 2015-02-27 2017-09-28 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
LV15201B (en) 2015-08-31 2017-07-20 Latvijas Organiskās Sintēzes Institūts The method for the preparation of ibrutinib intermediate
CN106608877B (en) * 2015-10-21 2018-11-13 新发药业有限公司 One kind replacing Buddhist nun's intermediate 4- amino -3- according to Shandong(4- phenoxy groups)The preparation method of phenyl -1H- pyrazolos [3,4-d] pyrimidine
JO3793B1 (en) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv Inhibitors of bruton’s tyrosine kinase and methods of their use
JO3794B1 (en) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv Polycyclic compounds as inhibitors of bruton's tyrosine kinase
WO2018103058A1 (en) * 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
CN109311883B (en) * 2017-02-09 2021-03-19 合肥合源药业有限公司 Crystal forms of FLT3 kinase inhibitor or salt thereof and preparation method thereof
CN107383017B (en) * 2017-07-20 2020-01-14 河南师范大学 Efficient preparation method of ibrutinib
CN110944999A (en) 2017-08-01 2020-03-31 勃林格殷格翰国际有限公司 Intermediate compounds and methods
WO2020234381A1 (en) 2019-05-21 2020-11-26 Janssen Pharmaceutica Nv Processes and intermediates for preparing a btk inhibitor
MX2021014245A (en) * 2019-05-21 2022-01-06 Janssen Pharmaceutica Nv Processes and intermediates for preparing a btk inhibitor.
CN113200987A (en) * 2021-04-29 2021-08-03 湖南华腾制药有限公司 Preparation method of ibrutinib
CN115322226B (en) * 2022-08-17 2023-08-11 厦门大学 Covalent targeting arsenic inhibitor and preparation method and application thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1212327B8 (en) * 1999-09-17 2004-02-25 Abbott GmbH & Co. KG Pyrazolopyrimidines as therapeutic agents
MX347525B (en) * 2006-09-22 2017-04-27 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase.
ES2403546T3 (en) 2006-11-03 2013-05-20 Pharmacyclics, Inc. Bruton tyrosine kinase activity probe and method of use
CA2681756C (en) * 2007-03-28 2015-02-24 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
UA105362C2 (en) * 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
GEP20146098B (en) 2009-03-31 2014-05-27 Boehringer Ingelheim Int 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their usage as pde9a modulators
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
AU2011276955B2 (en) * 2010-07-09 2014-11-06 The Walter And Eliza Hall Institute Of Medical Research Protein kinase inhibitors and methods of treatment
WO2012058645A1 (en) * 2010-10-29 2012-05-03 Biogen Idec Ma Inc. Heterocyclic tyrosine kinase inhibitors
US9376438B2 (en) * 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
WO2013010136A2 (en) * 2011-07-13 2013-01-17 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20140045813A1 (en) * 2012-08-10 2014-02-13 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as btk inhibitors
CA2888960C (en) * 2012-11-02 2017-08-15 Pfizer Inc. Bruton's tyrosine kinase inhibitors
CN103848810A (en) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 Bruton's tyrosine kinases inhibitor

Also Published As

Publication number Publication date
CN105026400A (en) 2015-11-04
MY194905A (en) 2022-12-22
BR112015021856A2 (en) 2017-07-18
HRP20220628T1 (en) 2022-06-24
EA201591685A1 (en) 2016-01-29
EP2970291B1 (en) 2022-05-11
KR20210123429A (en) 2021-10-13
LT2970291T (en) 2022-06-10
WO2014139970A1 (en) 2014-09-18
SI2970291T1 (en) 2022-07-29
EP2970291A1 (en) 2016-01-20
AU2018204086A1 (en) 2018-06-28
HUE058914T2 (en) 2022-09-28
DK2970291T3 (en) 2022-08-01
PE20151652A1 (en) 2015-11-12
CA2901510A1 (en) 2014-09-18
JP6777398B2 (en) 2020-10-28
AU2018204086B2 (en) 2020-03-12
MX2020012596A (en) 2021-02-09
CN112608298A (en) 2021-04-06
KR102311329B1 (en) 2021-10-14
KR102377688B1 (en) 2022-03-22
ES2924193T3 (en) 2022-10-05
KR20150132172A (en) 2015-11-25
CA2901510C (en) 2022-11-29
MX2015012731A (en) 2016-02-18
JP2016510779A (en) 2016-04-11
SG10201809696UA (en) 2018-11-29
AU2014230935A1 (en) 2015-09-03

Similar Documents

Publication Publication Date Title
ZA201905426B (en) Drug combinations
SG11201507595XA (en) Processes and intermediates for preparing a medicament
IL245211A0 (en) Medicament inhaler
AU351520S (en) Inhaler
AU352076S (en) Inhaler
HUE038547T2 (en) Inhaler
GB2533747B (en) A patient interface
PL2978481T3 (en) Inhaler
LT3035885T (en) Inhaler
HUE053417T2 (en) Inhaler
ZA201508680B (en) Inhaler
GB2530229B (en) A splint
SG11201602693QA (en) Methods and intermediates for preparing macrolactams
GB201313835D0 (en) A medicament
HRP20181933T1 (en) Pharmaceutical process and intermediates
HK1216178A1 (en) Processes and intermediates for preparing a medicament
GB201311546D0 (en) A bandage
GB201320786D0 (en) Medicament
GB201305071D0 (en) A wheelchair
AU348321S (en) A wheelchair